¡Buen día, buen día! ¿Cómo vamos, les alcanzó el fin de semana para sus pendientes y relajarse un poco? Aquí les dejo los #TitularesDelDia, arranca la semana con temas diversos de política e #InseguridadCiudadana con mención de la selección en lo deportivo. #CerdazzoTeInforma
Atentos hoy a:
- El desarrollo de la crisis entre la #JNJ, el @congresoperu y @FiscaliaPeru
- La lista final del DT Reynoso de los seleccionados para el partido Perú v Brasil por las #Eliminatorias2026 en Lima
#TitularesDelDia #inseguridadciudadana #CerdazzoTeInforma #jnj #eliminatorias2026
Idorsia kauft Rechte für Aprocitentan von Janssen zurück
Das Biotech-Unternehmen Idorsia hat die Entwicklungs- und Vermarktungsrechte für den Bluthochdruck-Senker Aprocitentan zurückgekauft. Dafür zahlt Idorsia bis zu 306 Millionen Franken an Janssen, der Pharmasparte von Johnson & Johnson. #JanssenCilagAG #jnj #news
¡Buen día, buen día! ¿Cómo vamos, qué planes para el feriado por #SantaRosaDeLima? Aquí les dejo los #TitularesDelDia qué hoy hablan del amparo de la #FiscalDeLaNscion ante la #JNJ y el #PlanBoluarte qué será la adaptación local del de Bukele. #CerdazzoTeInforma #HelloWorld
#santarosadelima #TitularesDelDia #fiscaldelanscion #jnj #planboluarte #CerdazzoTeInforma #helloworld
#jnj #PatientsNotPatents #Bedaquiline
an important update worth celebrating
https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline
not a full release of the patent but stoptb has been granted license to produce generics of bedaquiline. judging by the timing I would say the social media outrage was the difference.
to everyone who devoted their attention:
thank you. thank you. thank you.
#jnj #patientsnotpatents #bedaquiline
An excellent read on #bedaquiline and #JNJ from MSF (Doctors Without Borders) from back in 2019 https://msfaccess.org/jj-can-you-hear-us-questions-and-answers
What really gets me about JNJ saying ‘the most significant barrier to TB treatment access is being undiagnosed’ is that it completely ignores the fact that not everyone diagnosed with TB gets treatment because, get this, the treatment is too expensive #patientsnotpatents #JNJ #bedaquiline #tuberculosis
#patientsnotpatents #jnj #bedaquiline #tuberculosis
#JNJ is actively going against a recommendation of PIH given in 2020 by attempting to extend the patent of #Bedaquiline. this drug saves lives.
https://doi.org/10.1164/rccm.202001-0135OC
#PatientsNotPatents
#jnj #bedaquiline #patientsnotpatents
Johnson & Johnson makes a drug called bedaquiline which is essential for treating certain kinds of TB. The patent for bedaquiline is set to expire next week, yet, J&J is trying a sneaky tactic to extend their patent, which means that thousands of people may die needlessly from TB in the next few years.
Ask J&J to change their mind. And if they don't remember their brands.
For more info, here's John Green: https://youtu.be/tMhgw5SW0h4
#bedaquiline #johngreen #jnj #tb #generic #tuberculosis
my mother used to say "life sucks and then you die"
except if you're #JNJ and have the opportunity to allow people to continue to suck you NEED TO TAKE THAT OPPORTUNITY.
they've recouped their portion of the investment over the 20 year patent on #Bedaquiline as a treatment for #Tuberculosis and #MDRTB. when the patent expires, it's time for the drug to be produced generically at a lower cost to create higher availability and save hundreds of thousands of lives.
#jnj #bedaquiline #tuberculosis #mdrtb #patientsnotpatents
Johnson & Johnson is poised to kill hundreds of thousands of people with treatable #Tuberculosis by exploiting loopholes in order to extend their monopoly on the drug #Bedaquiline after already having had 20 years of patent protection.
J&J think you won’t care because it’ll mostly be impoverished people in poor countries who will die. Prove them wrong.
#tuberculosis #bedaquiline #jnj #mdrtb #johnsonandjohnsongreed
The #USTaxpayers invested up to $1.2 Billion, #BillionDollars, in #Bedaquiline out spending #JnJ by up to a factor of 5:1 (#Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500616/#pone.0239118.s001)
Where is our #ROI if the patent office approves their clinically insignificant formulation tweak and extends their patent?
#ustaxpayers #billiondollars #bedaquiline #jnj #source #ROI
If the #USTaxpayers invested in #Bedaquiline, we need to sue #JnJ (Johnson & Johnson) for the generic access just like we did for #Truvada! @aoc.
https://www.washingtonpost.com/opinions/2023/05/16/multidrug-resistant-tuberculosis-treatment/
#ustaxpayers #bedaquiline #jnj #truvada
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations —After FDA rejection, Gilead nears full EU nod for hep D drug — Judge orders J&J, talc opponents to engage in settlement talks -- See more on our front page news http://bit.ly/w28kSd #earnings #biogen #novartis #sanofi #gileadsciences #hepatitisd #legal #bankruptcy #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#earnings #biogen #novartis #Sanofi #gileadsciences #hepatitisd #legal #bankruptcy #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Busy with 3 program launches this year, Biogen trims pipeline —Novartis, helped by cost cuts, raises full-year outlook—Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO-- See more on our front page news http://bit.ly/w28kSd #earnings #biogen #novartis #jnj #consumerhealth #ipos #spinoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#earnings #biogen #novartis #jnj #consumerhealth #ipos #spinoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Abbott sales 18% fall due to anticipation of COVID testing sales declines —AstraZeneca confident new COVID antibody protects against known variants— J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma -- See more on our front page news http://bit.ly/w28kSd #abbottlabs #earnings #covid #covid19 #antibodies #astrazeneca #jnj #aacr #multiplemyeloma #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#abbottlabs #earnings #covid #covid19 #antibodies #astrazeneca #jnj #aacr #multiplemyeloma #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
GSK coughs up $2B for Bellus Health —J&J records $130M restructuring expense in Q1 overhaul of infectious disease unit— Supreme Court slaps down separate bids from Novartis, Sanofi -- See more on our front page news http://bit.ly/w28kSd #gsk #chroniccough #jnj #earnings #supremecourt #novartis #sanofi #mergersandacquisitions #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#gsk #chroniccough #jnj #earnings #SupremeCourt #novartis #Sanofi #mergersandacquisitions #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Wall Street conclut en légère hausse à la veille d'une salve de résultats de
#NetflixInc #BoA #TeslaMotorsInc #LockheedMartinCorp #StateStreetCorp #JPMorgan #jnj #SamsungElectronicsCoLtd #GoldmanSachs #Microsoft #DJIA #Nasdaq #SP500 #news
#netflixinc #boa #teslamotorsinc #lockheedmartincorp #statestreetcorp #jpmorgan #jnj #samsungelectronicscoltd #goldmansachs #microsoft #djia #nasdaq #sp500 #news
J&J opens the valve on $50M MS partnership with Pipeline — The end of an era: Regeneron chairman Roy Vagelos to retire after 29-year run— Merck to buy inflammatory disease drugmaker Prometheus for $10.8B -- See more on our front page news http://bit.ly/w28kSd #JNJ #ms #multiplesclerosis #chairman #regeneron #merck #inflammatorydisease #mergersandacquisitions #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#jnj #ms #multiplesclerosis #chairman #regeneron #merck #inflammatorydisease #mergersandacquisitions #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
J&J bows out of RSV vaccine race after scrapping trial — FDA lifts partial hold on Blueprint's CDK2 inhibitor — Pressure is building on pharma and biotech companies to take climate action -- See more on our front page news http://bit.ly/w28kSd #jnj #rsv #vaccines #clinicaltrials #fda #climatechange #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#jnj #RSV #vaccines #clinicaltrials #FdA #climatechange #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma